26th Feb 2019 7:00 am |
RNS |
Lynparza significantly delayed disease progression |
25th Feb 2019 7:00 am |
RNS |
Brilinta's PhIII THEMIS trial met primary endpoint |
14th Feb 2019 7:00 am |
RNS |
AstraZeneca Full-Year and Q4 2018 Results |
6th Feb 2019 7:00 am |
RNS |
US FDA grants Fasenra Orphan Drug Designation |
5th Feb 2019 7:05 am |
RNS |
US FDA grants Breakthrough Therapy Designation |
5th Feb 2019 7:00 am |
RNS |
EMA grants PRIME eligibility for MEDI8897 |
1st Feb 2019 3:00 pm |
RNS |
Total Voting Rights |
1st Feb 2019 1:17 pm |
RNS |
Forxiga receives positive EU CHMP opinion |
25th Jan 2019 2:00 pm |
RNS |
Completion of divestment of US Synagis rights |
7th Jan 2019 1:00 pm |
RNS |
AstraZeneca announces organisational changes |
2nd Jan 2019 3:00 pm |
RNS |
Total Voting Rights |
20th Dec 2018 1:47 pm |
RNS |
Bevespi Aerosphere approved in the EU for COPD |
20th Dec 2018 7:05 am |
RNS |
Lynparza meets primary endpoint in SOLO-3 trial |
20th Dec 2018 7:00 am |
RNS |
Phase III ROCKIES and OLYMPUS roxadustat trials |
19th Dec 2018 6:31 pm |
RNS |
FDA approves Lynparza as 1L maintenance therapy |
18th Dec 2018 9:09 am |
RNS |
Roxadustat approved in China for the treatment of |
14th Dec 2018 7:00 am |
RNS |
Directorate Change |
7th Dec 2018 7:00 am |
RNS |
Update on the Phase III EAGLE trial of Imfinzi |
6th Dec 2018 7:00 am |
RNS |
Divestment of rights to Covis completed |
4th Dec 2018 3:00 pm |
RNS |
Director/PDMR Shareholding |
3rd Dec 2018 4:00 pm |
RNS |
Block listing Interim Review |
3rd Dec 2018 4:00 pm |
RNS |
Total Voting Rights |
3rd Dec 2018 7:00 am |
RNS |
Grünenthal Agreement for Nexium, Vimovo Completed |
26th Nov 2018 7:00 am |
RNS |
US FDA grants Fasenra ODD for EGPA |
16th Nov 2018 7:00 am |
RNS |
AstraZeneca provides update on Phase III MYSTIC |
13th Nov 2018 7:00 am |
RNS |
AstraZeneca to divest US Synagis rights to Sobi |
12th Nov 2018 7:05 am |
RNS |
US FDA accepts regulatory submission for Lynparza |
12th Nov 2018 7:00 am |
RNS |
Farxiga significantly reduced hospitalisation for |
8th Nov 2018 7:00 am |
RNS |
AZN: Year-to-Date and Q3 2018 Results |
6th Nov 2018 7:00 am |
RNS |
Divestment of rights to Covis Pharma |
1st Nov 2018 3:00 pm |
RNS |
Total Voting Rights |
31st Oct 2018 9:45 am |
RNS |
Additional financial information-Grünenthal deal |
30th Oct 2018 7:00 am |
RNS |
Grünenthal Agreement for rights to Nexium, Vimovo |
23rd Oct 2018 7:00 am |
RNS |
AstraZeneca Extends Innate Pharma Collaboration |
22nd Oct 2018 7:00 am |
RNS |
Lynparza shows 70% reduction in PFS ovarian cancer |
19th Oct 2018 1:09 pm |
RNS |
CHMP positive opinion Bevespi Aerosphere |
16th Oct 2018 7:00 am |
RNS |
FDA Orphan Drug for Lynparza in pancreatic cancer |
1st Oct 2018 3:00 pm |
RNS |
Total Voting Rights |
1st Oct 2018 7:00 am |
RNS |
Atacand Agreement with Cheplapharm Completed |
28th Sep 2018 4:00 pm |
RNS |
Previous Announcement Regarding Appointment Of NED |